Objectives:
This workshop is intended for investigators interested in the development of quantitative methods to address clinical and scientific concerns regarding resistance to antiviral drugs. The focus will be primarily, but not exclusively, on HIV infection. Subjects of interest include modeling the development of HIV resistance mutations and the factors that influence this development, as well as relating patterns of these mutations to clinical response to antiviral drugs or to in-vitro measures of phenotype. Statistical issues include methods for studying viral evolution (tree-based methods, stochastic processes etc.) as well as methods for adjusting for multiple testing. The major goal is to involve scientists from a variety of quantitative disciplines, including mathematics, statistics, and computer science (artificial intelligence) as well as interested virologists and to facilitate communication among investigators, especially across the different disciplines.
The workshop will be open to all quantitative investigators who are working in the areas described above; participants will be invited to present their work either by oral presentation or by poster. The number and exact length of the presentations will depend on the number of submitted abstracts; the organizers hope to provide opportunities for all those who are interested in presenting.
Please note:
- A nominal registration fee will be charged
- a limited number of travel & accommodation scholarships will be available
More information regarding abstract submission, registration, housing and meeting logistics will be emailed as it becomes available.
This workshop is supported by grants from Bayer HealthCare - Diagnostics, VircoLab and GlaxoSmithKline.
Status:
The workshop was held on May 11-12, 2006 in Boston
The Steering Committee for this project includes:
Lee Bacheler - Virco
Francoise Brun-Vezinet - Hopital Bichat-Claude Bernard
Ben Cheng - Forum for Collaborative HIV Research
Dominique Costagliola - ANRS (co-chair)
Victor DeGruttola - Harvard (co-chair)
David Hall - Boehringer Ingelheim
Richard Haubrich - UC San Diego
Veronica Miller - Forum for Collaborative HIV Research
Mark van der Laan - UC Berkeley
